Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

Running, not enrolling · Phase 1

Conditions studied: Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer

In brief

This clinical trial studies the side effects and best way to perform yttrium Y-90 radioembolization in treating patients with liver cancer that has spread to other places in the body (metastatic). Yttrium Y-90 radioembolization is a therapy that injects radioactive microspheres directly into an artery that feeds liver tumors to cut off their blood supply. Performing yttrium Y-90 radioembolization in a single session may make treatment faster, minimize patient travel, and decrease the overall cost of the procedure.

Key facts

Study ID

NCT03028311

Run by

M.D. Anderson Cancer Center

People needed

12

Starts

2017-01-09

Expected to finish

2027-01-31

Last updated by the study team

2026-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The ability to understand and sign informed consent
• Any candidate eligible for standard of care Y90 radioembolization for treatment of their primary or metastatic liver tumors

You may not qualify if…

• Patients with greater than 50% liver tumor burden

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.